Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin

Ishikawa,Toru; Abe,Satoshi; Kojima,Yuichi; Sano,Tomoe; Iwanaga,Akito; Seki,Kei‑Ichi; Honma,Terasu; Yoshida,Toshiaki; Yamazaki,Mihoko; Sakai,Takehito; Tasaki,Kazuyuki; Suzuki,Yasushi

doi:10.3892/etm.2015.2340

May-2015 Volume 9 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2015 Volume 9 Issue 5

Full Size Image

Article Open Access

Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin

Authors:
- Toru Ishikawa
- Satoshi Abe
- Yuichi Kojima
- Tomoe Sano
- Akito Iwanaga
- Kei‑Ichi Seki
- Terasu Honma
- Toshiaki Yoshida
- Mihoko Yamazaki
- Takehito Sakai
- Kazuyuki Tasaki
- Yasushi Suzuki
View Affiliations / Copyright

Affiliations: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950‑1104, Japan, Department of Nephrology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950‑1104, Japan

Copyright: © Ishikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 1646-1650
|
Published online on: March 10, 2015

https://doi.org/10.3892/etm.2015.2340
Expand metrics +

Abstract

The aim of the present study was to determine predictors of a sustained virological response (SVR) with a regimen of double filtration plasmapheresis (DFPP) combined with interferon‑β plus ribavirin (IFN‑β/RBV) induction therapy prior to pegylated (PEG‑IFN/RBV) standard of care (SOC) therapy for patients with chronic hepatitis C who had experienced SOC treatment failure. Predictors of a SVR were analyzed in chronic hepatitis C patients with genotype 1b hepatitis C virus (HCV), who had a high viral load. The patients had been unresponsive to previous IFN therapy and underwent induction therapy with IFN‑β/RBV plus DFPP, which was performed five times during the same period, followed by PEG‑IFN/RBV. In total, 10 patients received the combination DFPP plus IFN‑β/RBV induction therapy prior to PEG‑IFN/RBV therapy for the treatment of chronic hepatitis C. Two weeks after treatment initiation, a decrease in the HCV RNA levels of ≥2 log IU/ml occurred in 9/10 patients (90%), while a decrease of ≥4 log IU/ml was observed in 4/10 patients (40%). The HCV RNA levels at week 2 after treatment initiation in the SVR and non‑SVR patients decreased by 5.0±0.8 and 2.9±1.1 log IU/ml, respectively. Despite no response to previous IFN therapy, three of the 10 patients (30%) experienced a SVR. The results indicated that a rapid virological response ensued following IFN‑β/RBV induction and DFPP supplementary therapy. Although the level of interleukin‑28B is an important predictor of a SVR, a decrease in the HCV RNA volume of ≥4 log IU/ml at week 2 after the initial treatment is also an important predictor. Therefore, rapid virological reduction using DFPP, in addition to IFN‑β/RBV induction therapy, is an important predictor of a SVR.

View Figures

View References

1	Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:958–965. 2001. View Article : Google Scholar : PubMed/NCBI
2	Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H and Hayashi N: Telaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 56:78–84. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chayama K, Hayes CN, Ohishi W and Kawakami Y: Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 48:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chopra A, Klein PL, Drinnan T and Lee SS: How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 33(Suppl 1): 30–34. 2013. View Article : Google Scholar : PubMed/NCBI
5	Cacoub P, Bourlière M, Lübbe J, et al: Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 56:455–463. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ishikawa T, Kubota T, Abe H, et al: Efficacy of the regimen using twice-daily β-interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load. Hepatol Res. 42:864–869. 2012. View Article : Google Scholar : PubMed/NCBI
7	Schettler V, Monazahian M, Wieland E, et al: Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Invest. 31:154–155. 2001. View Article : Google Scholar : PubMed/NCBI
8	Neumann AU, Lam NP, Dahari H, et al: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 282:103–107. 1998. View Article : Google Scholar : PubMed/NCBI
9	Yamashita T, Arai K, Sakai A, et al: Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study. Hepatol Res. 36:167–175. 2006. View Article : Google Scholar : PubMed/NCBI
10	Strader DB, Wright T, Thomas DL and Seeff LB: American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology. 39:1147–1171. 2004. View Article : Google Scholar : PubMed/NCBI
11	Taniguchi M, Furukawa H, Shimamura T, et al: Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C. Transplantation. 81:1747–1749. 2006. View Article : Google Scholar : PubMed/NCBI
12	Okushin H, Morii K, Kishi F and Yuasa S: Efficacy of the combination therapy using twice-a-day IFNβ followed by IFNα2b in treatment for chronic hepatitis C. Kanzo. 38:11–18. 1997.[In Japanese]. View Article : Google Scholar
13	Fujiwara K, Mochida S, Matsuo S, et al: Randomized control trial of interferon-β injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatology Res. 12:240–251. 1998. View Article : Google Scholar
14	Izumi N, Kumada H, Hashimoto N, et al: Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Dig Dis Sci. 46:516–523. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hilfenhaus J, Damm H, et al: Pharmacokinetics of human interferon-beta in monkeys. J Interferon Res. 1:427–436. 1981. View Article : Google Scholar : PubMed/NCBI
16	Asahina Y, Izumi N, Uchihara M, et al: A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology. 34:377–384. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ishikawa T, Higuchi K, Kubota T, et al: Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy. Ther Apher Dial. 15:400–405. 2011.PubMed/NCBI